Valence 로고
인기
로그인

관심목록에 추가

NeoGenomics Inc.

NasdaqCM: NEO · 실시간 가격 · USD
16.98
+0.45 (2.72%)
종가 기준: Aug 21, 2026, 3:59 PM
17.07
+0.53%
애프터마켓: 7:30 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

NeoGenomics Inc.(NEO) 주가, 분석 및 데이터

2.72%
매수호가11.97
시가총액2.18B
매출 (ttm)766.29M
순이익 (ttm)-51.88M
1.73
-0.4
n/a
49.41
P/B (ttm)2.76
P/S (ttm)2.89
실적 발표일Apr 29, 2025
매도호가20.49
거래량1,101,159
평균 거래량 (20일)2,764,336
시가16.60
전일 종가16.53
일중 범위16.21 - 17.07
52주 범위6.24 - 17.08
애널리스트Buy
목표주가19 (11.90%)
배당n/a
배당락일n/a

NEO 소개

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing se...

[더 보기]
산업 Diagnostics & Research
섹터 Healthcare
IPO 일자 Mar 16, 2004
직원 수 2,500
상장 거래소 NasdaqCM
티커 NEO
웹사이트 https://www.neogenomics.com
전체 기업 정보

재무 실적

2025년 NeoGenomics의 매출은 727.33M로, 전년 660.57M 대비 10.11% 증가했습니다. 순이익은 -108.03M로, 37.22% 증가했습니다.

재무제표

애널리스트 전망

애널리스트 9명의 투자의견을 종합하면 NEO 주식의 평균 등급은 "Buy"입니다. 12개월 목표주가는 19로, 최근 주가 대비 11.9% 상승 여력입니다.

주가 전망

어닝 서프라이즈

NeoGenomics가 Jul 28, 2026에 분기 실적을 발표했습니다:
  • 매출 $201.66M 예상치 하회 $0, 및 11.21% 전년 대비 성장.
  • EPS 0.05 예상치 상회 0.02, 및 66.67% 전년 대비 성장.

    • 다음 실적 발표

    NeoGenomics Inc.의 실적 발표 예정일은 Apr 29, 2025, 장 시작 전입니다.
    애널리스트 예상 매출은 ... 업그레이드
    news image

    19시간 전 · StockStory

    3 Unprofitable Stocks Walking a Fine Line

    Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital ...

    news image

    1주 전 · StockStory

    3 Stocks Under $50 with Open Questions

    Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some ...

    news image

    2주 전 · Simply Wall St.

    NeoGenomics (NEO) Is Up 8.4% After Q2 Profit Return And Raised 2026 Outlook – Has The Bull Case Changed?

    In July 2026, NeoGenomics, Inc. reported second-quarter 2026 results showing revenue of US$201.66 million and net income of US$2.24 million, compared with revenue of US$181.33 million and a net loss o...

    news image

    2주 전 · Zacks

    NeoGenomics, Inc. (NEO) Hit a 52 Week High, Can the Run Continue?

    NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

    news image

    2주 전 · Simply Wall St.

    NeoGenomics (NEO) Following Q2 Profit And Raised Outlook, Is Fair Value Already Priced In?

    NeoGenomics (NEO) is back in focus after second quarter earnings on 28 July 2026 reported quarterly profitability, revenue of US$201.66 million, and updated full year guidance that raised revenue expe...

    2 페이지 중 1